INTRODUCTION
Tuberculosis (TB) recently replaced HIV-1 as the leading infectious cause of death worldwide, causing an estimated 1.7 million deaths in 2016, of whom 374 000 were HIV-1-infected persons [1] . The true burden of TB in those with HIV-1 may be an underestimate, as post mortem studies have found TB in 40% of those who had died of HIV-1 [2] . HIV-1 significantly increases the risk of active tuberculosis [3] . Equally, TB is thought to accelerate HIV-1 progression, creating an environment that promotes viral replication [4] .
Understanding the pathogenesis of HIV-TB coinfection is essential to the development of much needed new biomarkers, diagnostics and vaccines, as previously reviewed [4] . This review focuses on three recent and notable facets in our understanding of HIV-TB co-infection; firstly, the role of immune complex formation in early co-infection, secondly,
IMMUNE COMPLEX FORMATION IN THE PATHOGENESIS OF EARLY HIV-TUBERCULOSIS
The clinical presentation of TB in HIV-1-infected persons varies by CD4 count. Those with high CD4 counts (>350 cells/ml) present similarly to HIV-1-uninfected persons, albeit with increased incidence [4] . The higher incidence of unique isolates of Mycobacterium tuberculosis by molecular typing in early HIV supports the notion that previously acquired M. tuberculosis infection is reactivated [5] . By contrast, presentation in those with low CD4 counts (<100/ ml) is frequently disseminated reflecting progression of disease following recent infection or reinfection, supported by increased clustering of M. tuberculosis by molecular typing in persons with advanced HIV-1 infection [5] .
The importance of the granuloma and the role CD4 T cells play in the initial control of TB infection is clear; however, less is known about the pathogenesis of early disease that occurs following failure of granulomatous control. We have recently shown that 2-deoxy-2-[
18 F]fluoro-D-glucose positron emission and computed tomography (FDG-PET/CT) can be used as a research tool to investigate early disease. In a study of 35 asymptomatic, HIV-1-infected persons with CD4 greater than 350 cells/ml, no previous history of TB treatment, positive IFN-g release assay, and negative microbiological screening culture, we demonstrated that 10 had abnormalities consistent with subclinical disease. Of these, 90% had evidence of infiltrates and/or fibrotic scarring in the upper lobes in a distribution typically seen in HIV-uninfected adults. Those with evidence of subclinical disease were significantly more likely to experience symptomatic disease progression [6 & ].
HIV-1-infected adults with subclinical TB, identified by FDG-PET/CT, had an increased abundance of transcripts in whole blood relating to the classical complement pathway and Fcg receptors, when compared with HIV-1-infected adults without active TB [7 && ]. This increase has subsequently been observed in HIV-1-uninfected persons prior to TB disease presentation [8] . Increasing complement transcript abundance correlates with increasing levels of circulating immune complexes (CIC), which bind complement and Fcg receptors and C1q, that were also elevated in those with subclinical disease (Fig. 1. ) [7 && ]. Elevated levels of CIC in active TB, even in those culture negative, in HIV-1-uninfected persons is recognized [9] . The role that immune complexes may play in the pathogenesis of early tuberculosis disease in persons of differing levels of immunocompetence is yet to be fully determined [9] ; however, recent evidence suggests this may be a critical stage in disease progression [10] .
Mycobacterial antigen can be detected within M. tuberculosis-uninfected cells, in early stages of disease even when overall numbers of visible acidfast bacilli are low [11, 12] . Of note, it has previously been shown that mRNA levels of the secreted Ag85B increase 14.6-fold in comparison with 16S ribosomal rRNA in the first 24-h of intracellular infection, and are enhanced by exogenous and endogenous TNF-a [13] . Recently, Srivastava et al. [14, 15] described intracellular M. tuberculosis as able to release free antigen extracellularly via kinesin-2 dependent antigen export vesicles, which facilitate cell-to-cell antigen transfer in part as an immune evasion strategy. B-cell clusters are frequently identified within TB lesions and free antigen released extracellularly could form immune complexes with locally produced antibody [12, 16, 17] . Solubilization of immune complexes is critical to prevent local precipitation in tissue and in-situ triggering of the proinflammatory complement cascade [18] . This solubilization is initially facilitated by binding of C1q to immune complexes, which prevent larger complexes forming, and may account for increases in C1q expression at the site of disease [19, 20] . Similarly, increased expression of Fcg receptor would facilitate intracellular take up of antigen. Ridley and Ridley observed in a detailed histopathological study of 31 cases of TB, that when antigen was phagocytosed within mononuclear cells, there was little noxious effect to surrounding tissue. However, wherever antigen was externalized, bound to the interstitial connective tissue and associated with complement, this was associated with evidence of localized necrosis [12] . Hunter et al. [11] established that antigen increase precedes tissue necrosis leading to a significant increase in bacillary numbers. Taken together this suggests that, in both HIV-1-infected (with high CD4 counts) and in HIV-1-uninfected adults, extracellular free antigen release may occur early in TB disease whereas bacillary numbers are low. Immune complex formation may simultaneously benefit the pathogen
KEY POINTS
Circulating immune complexes are markers of early disease progression in HIV-TB.
Type I and II interferon signalling are potential targets to reduce HIV-TB-driven disease.
Systemic immune activation precedes CD4 T-cell depletion as a factor of HIV-TB risk but is reflected in HLA-DR expression on CD4 T cells that may be a useful marker of disease activity during HIV-TB co-infection.
INTERPLAY OF INTERFERON SIGNALLING IN THE PATHOGENESIS OF HIV-TUBERCULOSIS
One of the most well studied groups of signalling proteins involved in HIV-1 and M. tuberculosis infections are the interferons (IFNs). Type 1 interferons (IFN-a/b) are classically induced by HIV-1 infection and type 2 IFN (IFN-g) by M. tuberculosis infection [21] . Blood transcriptional profiling of TB patients has identified a role for neutrophil-driven Type I and II IFN in TB disease [7 && ,22], suggesting there may be an interaction between these signalling pathways in individuals infected with HIV-1 and M. tuberculosis.
Whole blood transcriptomics has provided insight into disease pathogenesis in tuberculosis and more recently in predicting disease development [ progression is key, as the higher baseline threshold of IFN signalling in individuals with HIV-1 [27] may lead to quicker TB disease progression.
Transcriptomic modular approaches combined with whole blood deconvolution have indicated that IFN signalling in HIV-1 is not restricted to a single cell type, but occurs in multiple cell types, including neutrophils and B cells (Fig. 1) [28] . Interestingly, B cells from mice infected with M. tuberculosis induce Type I IFN via a key protein, Stimulator of IFN Genes (STING) and, to a lesser extent, the C-type lectin Mincle signalling. This modulates macrophage polarization towards an M2-type anti-inflammatory phenotype [29] , which would be predicted to lead to a poorer outcome following M. tuberculosis infection. Furthermore, B cells isolated from pericardial fluid from TB patients display higher Type I IFN transcripts than in the blood, indicating B cells also contribute to Type I IFN signalling at disease site [29] .
IFNs play a crucial antiviral role during acute HIV-1 infection, preventing productive viral infection through induction of host restriction factors, including the apolipoprotein B mRNA editing enzyme, catalytic polypeptide-like 3G (APOBEC3) family of proteins, tetherin, and recently identified guanylate-binding protein 5 (GBP5), [30, 31, 32 & ] the latter also being a frequent component of whole blood signatures predicting TB risk [8] . HIV-1 infection in turn inhibits Type I IFN production by T cells through expression of HIV-encoded proteins, Nef and Tat, inhibiting IFN-b promoter stimulator-1 (IPS-1), an innate immune viral RNA-sensing adaptor protein. Blocking of antiviral IPS-1 signalling, restriction factors, and therefore IFN induction, results in increased HIV-1 replication (reviewed in [33] ).
Although Type II IFN is generally thought to promote protection during initial M. tuberculosis infection, both Type I and Type II IFN signalling have each been shown to promote protection as well as drive disease, depending on the timing of infection and disease and the context of modulation (reviewed in [34] [35] [36] ). Excessive Type I IFN signalling is associated with eicosanoid imbalance resulting in inefficient bacterial containment and disease exacerbation, suggesting that Type I IFN may counteract the immunoprotective effects of Type II IFN on M. tuberculosis infection [37] .
This intricate balance was further dissected by Yan et al. [38 && ] who showed that mice deficient in Absence in Melanoma 2 (AIM2) expressed higher levels of IFN-b and suppressed IFN-g signalling, resulting in higher infection burdens, and more severe disease. They showed that AIM2 induction of apoptosis-associated speck-like protein (ASC) results in interaction with STING, inhibiting the interaction between STING and downstream TANK-binding kinase 1 (TBK1), which interacts with interferon regulatory factor 3 (IRF3), consequently reducing the release of type I IFN, in bone marrowderived macrophages and bone marrow-derived dendritic cells (Fig. 1) .
A recent study has shown that the product of one of the most highly induced IFN-stimulated genes (ISGs), ISG15, can dually promote and protect against M. tuberculosis infection depending on the stage of disease. They demonstrated that ISG15 along with Type I IFN promote bacterial replication during early infection. However, as the infection progresses, ISG15 switches to a more protective role, demonstrated by an increased susceptibility to infection observed in mice deficient of ISG15 [39] . The authors hypothesize that differential regulation of ISGs between people may lead to different disease outcomes.
DEPLETION OF MYOCOBACTERIUM TUBERCULOSIS-SPECIFIC CD4 T CELLS AND THE IMPACT OF T-CELL ACTIVATION DURING HIV-TUBERCULOSIS CO-INFECTION
Although TB risk is associated with lower peripheral CD4 T-cell count [40] , it is also observed early after HIV-1 seroconversion in persons with relatively well preserved peripheral CD4 T-cell counts [5, 41] , as well as in persons on antiretroviral therapy (ART) [42, 43] . This has prompted further investigation into the role of selective depletion and qualitative differences in function of M. tuberculosis-specific CD4 T cells during HIV-1 infection.
There is evidence that M. tuberculosis-specific CD4 T cells are preferentially depleted during HIV-TB co-infection, a phenomenon not observed during co-infection with other pathogens such as cytomegalovirus [44] . This is thought to be driven by increased surface expression of CCR5 (a co-receptor used by R5 strains of HIV-1 to gain cellular entry) and low expression of macrophage inflammatory protein-1b (CCL4, a natural ligand of CCR5) on M. tuberculosis-specific CD4 T cells, with this being a prominent feature of lung-resident M. tuberculosisspecific CD4 T cells [45] [46] [47] . A study using M. tuberculosis-specific major histocompatibility complex (MHC) class II tetramers reported a 52% lower absolute number of M. tuberculosis-specific tetramerþ CD4 T cells in HIV-1-infected versus HIV-1-uninfected participants with latent TB infection (LTBI) [48 && ]. Interestingly, despite low CD4 T-cell counts (median 105 cells/ml), HIV-1-infected participants with active TB had comparable absolute numbers of M. tuberculosis-specific tetramer þ CD4 T cells to those of HIV-1-uninfected participants with active TB. This demonstrates that co-infection with HIV-1 does not impair M. tuberculosis-specific CD4 T cells' ability to expand in response to replicating M. tuberculosis.
HIV-1 infection also mediates depletion of M. tuberculosis-specific CD4 T cells at the site of disease (Fig. 1) . Four studies have reported decreased frequency of M. tuberculosis-specific CD4 T cells in bronchoalveolar lavage (BAL) samples of HIV-1-infected compared with HIV-1-uninfected healthy persons [47, [49] [50] [51] [52] . The most recent of these studies by Bunjun et al. included HIV-1-infected, IFN-g release assay (IGRA)-positive participants who were ART-naive with relatively preserved CD4 T-cell counts (median of 619 cells/ml) as well as HIV-1-uninfected controls. In contrast with previous studies, a significantly higher number of CD3 þ lymphocytes were observed in the BAL of HIV-1-infected participants compared with HIV-1-uninfected participants [53 & ]. This constituted a 26-fold higher number of CD8 T cells and 7-fold higher number of CD4 T cells [53 & ], with both CD4 and CD8 T-cell numbers showing significant correlation to BAL HIV-1 viral load, as seen in HIV-1-associated lymphocytic alveolitis [54] . There was no significant difference in absolute number of M. tuberculosisspecific CD4 T cells in BAL of HIV-1-infected versus HIV-1-uninfected participants once adjusted for the higher number of CD4 T cells found in the HIV-1-infected group. The decreased frequency of M. tuberculosis-specific CD4 T cells was thus counteracted by HIV-1-mediated CD4 T-cell influx, resulting in comparable absolute numbers of M. tuberculosis-specific CD4 T cells to that of HIV-1-uninfected participants. Although evidence from longitudinal studies are lacking, it could be postulated that the findings of Bunjun et al. are representative of early HIV-1 infection, with the three prior studies being representative of more advanced HIV-1 infection as evidenced by lower median CD4 count in their HIV-1-infected participant groups.
It is recognized that co-infection with M. tuberculosis contributes to immune activation observed in HIV-1 infection and that activation is associated with a higher risk of opportunistic infection and death [55] [56] [57] . Several markers have been associated with immune activation, for example, CD38, programmed death receptor 1 (PD-1), Ki-67 and HLA-DR [58, 59 && ,60,61]. Riou et al. [59 && ] showed that there is higher HLA-DR expression on M. tuberculosis-specific cells from HIV-1-infected compared with HIV-1-uninfected persons both in LTBI and active TB. In the HIV-1-infected LTBI group, HLA-DR expression was similar to that observed in the bulk CD4 T-cell compartment, and thus indicative of HIV-1-mediated systemic immune activation. Activated CD4 T cells expressing CD26 and HLA-DR have also been implicated as sources of HIV replication during HIV-TB co-infection, thus accelerating HIV-1 disease progression [60] . There is evidence that systemic immune activation also imparts higher TB risk. In a cohort of HIV-1-unexposed, BCG-vaccinated infants, the frequency of activated HLA-DR þ CD4 T cells correlated with TB risk, with the highest risk being observed in those with the highest levels of response [61] . In turn, these findings were confirmed in a cohort of HIV-1-uninfected adolescents [61] . HLA-DR expression on M. tuberculosis-specific CD4 T cells holds promise as biomarker of disease activity during HIV-TB co-infection and could be explored by future longitudinal studies as predictive biomarker of TB risk in HIV-1 infection.
CONCLUSION
Recent evidence emphasizes the diversity and complexity of the immune response to TB in persons infected with HIV. Using novel FDG-PET/CT imaging to identify HIV-infected individuals with early TB disease, circulating immune complexes are a hallmark of TB risk and may contribute to disease progression. Type I and Type II interferons have both been shown to promote protection as well as disease, depending on timing and context of modulation. M. tuberculosis-specific CD4 T cells are preferentially depleted by HIV-1, but still retain their ability to expand in response to M. tuberculosis. CD4 T-cell expression of HLA-DR may be a useful marker of systemic immune activation and disease activity in HIV-TB co-infection.
